Holen Sie sich die Stockscreener-App
7.30
1.68%
0.14
Schlusskurs vom Vortag:
$7.16
Offen:
$7.15
24-Stunden-Volumen:
102.50K
Relative Volume:
0.25
Marktkapitalisierung:
$363.32M
Einnahmen:
$13.55M
Nettoeinkommen (Verlust:
$-25.32M
KGV:
-13.47
EPS:
-0.542
Netto-Cashflow:
-
1W Leistung:
-16.23%
1M Leistung:
+32.60%
6M Leistung:
+50.41%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.00
$7.47
1-Wochen-Bereich:
$6.255
$9.17
52-Wochen-Spanne:
$3.4341
$15.37
Capsovision Inc Stock (CV) Company Profile
Firmenname
Capsovision Inc
Sektor
Branche
Telefon
(408) 370-4790
Adresse
18805 COX AVENUE SUITE 250, SARATOGA
Compare CV vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
7.29 | 356.84M | 13.55M | -25.32M | 0 | -0.542 |
ABT
Abbott Laboratories
|
102.51 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.77 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.69 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Roth Capital | Buy |
| 2025-07-28 | Eingeleitet | The Benchmark Company | Speculative Buy |
Capsovision Inc Aktie (CV) Neueste Nachrichten
Major CapsoVision (CV) holder Shen Ching Hang reports large direct and indirect stake - Stock Titan
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Grows By 35.2% - MarketBeat
CapsoVision targets 510(k) submission for Gen 2 colon capsule and AI module in Q3 2026 as commercial adoption accelerates - MSN
Benchmark cuts CapsoVision stock price target to $10 on delayed timeline By Investing.com - Investing.com Australia
Benchmark cuts CapsoVision stock price target to $10 on delayed timeline - au.investing.com
CapsoVision (NASDAQ:CV) Price Target Lowered to $10.00 at Benchmark - MarketBeat
CapsoVision 2025 Financial Performance Review - AlphaStreet
CapsoVision revenue up 13% to USD 3.9M in Q4 2025 - Medical Buyer
CapsoVision (CV) Q4 Loss Of US$0.16 EPS Tests Bullish Profitability Narratives - Sahm
CapsoVision’s CapsoCam: 360° Panoramic AI-Powered Capsule Endoscopy Solution Expanding Global GI Diagnostics Market 2324323344 - Minichart
Large CapsoVision (CV) holder discloses direct and trust share stakes - Stock Titan
CapsoVision Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: CapsoVision Q4 2025 sees revenue growth, stock dips - Investing.com Australia
CapsoVision Q4 Earnings Call Highlights - MarketBeat
CapsoVision Inc reports results for the quarter ended September 30Earnings Summary - TradingView
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
CV: AI-powered capsule endoscopy drives growth and innovation in noninvasive GI screening - TradingView
CapsoVision 10-K: Revenue $13.6M, EPS $(1.03) — Annual Results - TradingView
CapsoVision (NASDAQ: CV) flags going concern while advancing AI colon capsule - Stock Titan
CapsoVision, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CapsoVision Faces Deadline to Turn Capital Into Profit Before Runway Collapses - Bitget
CapsoVision (NASDAQ: CV) grows 2025 revenue 15% as net loss widens - Stock Titan
161,000 patients used CapsoVision's camera pill as sales climbed - Stock Titan
CapsoVision, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
CapsoVision Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
CapsoVision Conference: CEO Maps AI-Driven Capsule Endoscopy Roadmap for Colon and Pancreas Screening - MarketBeat
CapsoVision price target raised to $11 from $7 at Roth Capital - tipranks.com
CapsoVision (CV) director receives 4,045 RSU equity award - Stock Titan
CapsoVision (CV) awards 4,045 RSUs to board director - Stock Titan
CapsoVision (CV) director receives 4,045 RSU grant as board compensation - Stock Titan
CapsoVision (CV) director receives 4,045 RSUs vesting through 2026 - Stock Titan
CapsoVision (CV) awards 4,045 restricted stock units to director - Stock Titan
[Form 4] CapsoVision, Inc Insider Trading Activity - Stock Titan
CV: AI-powered capsule endoscopy targets multi-cancer detection with global expansion and strong funding - TradingView
CV: CapsoVision advances AI-powered capsule endoscopy with strong pipeline and global expansion - TradingView
CapsoVision’s Strategic Moves Spike Stock as Market Anticipates Growth - timothysykes.com
CapsoVision Surges 13% on Closing $14M Private Placement - StocksToTrade
CapsoVision closes $14 million private placement financing By Investing.com - Investing.com Australia
CapsoVision, Inc.: Fundamental Analysis and Financial Ratings | H6U | US1409351079 - marketscreener.com
CapsoVision Closes $14 Million Private Placement and Reports Preliminary 2025 Financial Results - Minichart
CapsoVision Raises Capital and Refocuses Colon Capsule Strategy - TipRanks
CapsoVision closes $14 million private placement financing - Investing.com
CapsoVision Raises ~$14 Million in Private Placement, Selling 2.87M Shares at $4.883 - TradingView
CapsoVision (NASDAQ: CV) secures $14M and pivots colon capsule strategy - Stock Titan
CapsoVision Announces $14 Million Private Placement Financing - GlobeNewswire
CapsoVision, Inc.: Fundamental Analysis and Financial Ratings | CV | US1409351079 - marketscreener.com
What Is CapsoVision's Roadmap For Growth And Innovation In 2026? - RTTNews
CapsoVision Inc Trading Resumes - MSN
CapsoVision, Inc. Announces Amendment to Sample Purchase Agreement with Canon Inc. for CMOS Image Sensor Development 5 - Minichart
CapsoVision increases development fee in amended agreement with Canon By Investing.com - Investing.com South Africa
CapsoVision increases development fee in amended agreement with Canon - Investing.com
Finanzdaten der Capsovision Inc-Aktie (CV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capsovision Inc-Aktie (CV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOUW JULIA S | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Imperial Joanne Carol | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| King Wen-Herng Henry | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
23,597 |
| Kuo Hui Ying | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
13,241 |
| Tsai Chen Lung | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Petersen Rebecca Ann | Director of Clinical Affairs |
Aug 18 '25 |
Option Exercise |
0.37 |
24,834 |
9,097 |
24,834 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):